Table 3.
Summary of the most common reported adverse events displayed by molecules and doses.
| Molecules (dose) | NCT (year) | Nausea (%) | Loss of appetite (%) | Diarrhea (%) | Vomiting (%) | Dyspepsia (%) | Constipation (%) |
|---|---|---|---|---|---|---|---|
| Exenatide (10 μg x 2/day) vs. Placebo |
NCT00765817 (2011) |
40.6 vs. 8.1 |
n.a. | 18.1 vs. 8.1 |
18.1 vs. 4.7 |
n.a. | 10.1 vs. 1.6 |
| Lixisenatide (17 μg/day) vs. Placebo |
NCT02058160 (2016) |
10.4 vs. 0.55 |
n.a. | 4.4 vs. 2.7 |
3.6 vs. 0.5 |
5.2 vs. 0.6 |
n.a. |
| Lixisenatide (20 μg/day) vs. Placebo |
NCT00715624 (2013) |
29.3 vs. 9.6 |
n.a. | 11.2 Vs. 6 |
9.8 vs. 1.2 |
5.2 vs. 0.6 |
n.a. |
| Lixisenatide (20 μg/day) vs. Placebo |
NCT00975286 (2013) |
27.3 vs. 4.9 |
n.a. | 6.7 vs. 3.1 |
9.4 vs. 1.35 |
n.a | n.a |
| Liraglutide (1.48 mg/day) vs. Placebo |
NCT01952145 (2016) |
9.4 vs. 1.1 |
n.a. | 7.2% vs. 2.5% |
5% vs. 1.8% |
n.a. | n.a. |
| Liraglutide (1.62 mg/day) vs. Placebo |
NCT01392573 (2014) |
6.5 vs. 3.5 |
n.a. | 6.5 vs. 3.5 |
n.a. | n.a. | n.a. |
| Liraglutide (1.8 mg/day) vs. Placebo |
NCT01617434 (2015) |
22.2 vs. 3.1 |
n.a. | 10.7 vs. 4.9 |
8.9 vs. 0.9 |
7.1 vs. 0.9 |
n.a. |
| Dulaglutide (1.5 mg/qw) vs. Placebo |
NCT02152371 (2017) |
12 vs. 1.3 |
n.a. | 11.3 vs. 4 |
6 vs. 0 |
6 vs. 0 |
n.a. |
| Exenatide (2 mg/qw) vs. Placebo |
NCT02229383 (2018) |
5.2 vs. 3.9 |
n.a. | 4.7 vs. 3.5 |
0.4 vs. 1.3 |
2.2 vs. 0 |
0.9 vs. 1.7 |
| Semaglutide (0.5 mg/qw) Semaglutide (1.0 mg/qw) vs. Placebo |
NCT02305381 (2018) |
11.4 vs. 16.8 vs. 4.5 |
n.a. | 4.5 vs. 6.9 vs. 1.5 |
6.1 vs. 11.5 vs. 3.0 |
n.a. | n.a. |
| Tirzepatide (5 mg/qw) Tirzepatide (10 mg/qw) Tirzepatide (15 mg/qw) vs. Placebo |
NCT04039503 (2022) |
12.9 vs. 17.6 vs. 18.3 vs. 2.5 |
6.9 vs. 12.6 vs. 14.2 vs. 1.7 |
12.1 vs. 12.6 vs. 20.8 vs. 10 |
6.9 vs. 7.6 vs. 12.5 vs. 2.5 |
6.9 vs. 8.4 vs. 5 vs. 1.7 |
6 vs. 6.7 vs. 6.7 vs. 1.7 |
n.a., not available.